This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tryptophan N-monooxygenase (EC 1.14.14.156, tryptophan N-hydroxylase, CYP79B1, CYP79B2, CYP79B3) is an enzyme with systematic name L-tryptophan,NADPH:oxygen oxidoreductase (N-hydroxylating). It catalyses the following overall chemical reaction:
In October 1938, Joachim von Ribbentrop first proposed German-Polish territorial adjustments and Poland's participation in the Anti-Comintern Pact against the Soviet Union. The status of the Free City of Danzig was one of the key bones of contention. Approached by Ribbentrop again in March 1939, the Polish government expressed willingness to address issues causing German concern, but effectively rejected Germany's stated demands and thus refused to allow Poland to be turned by Adolf Hitler into a German puppet state. Hitler, incensed by the British and French declarations of support for Poland, abrogated the German–Polish declaration of non-aggression in late April 1939. To protect itself from an increasingly aggressive Nazi Germany, already responsible for the annexations of Austria (in the Anschluss of 1938), Czechoslovakia (in 1939) and a part of Lithuania after the 1939 German ultimatum to Lithuania, Poland entered into a military alliance with Britain and France (the 1939 Anglo-Polish military alliance and the Franco-Polish alliance (1921), as updated in 1939). However, the two Western powers were defense-oriented and not in a strong position, either geographically or in terms of resources, to assist Poland. Attempts were therefore made by them to induce Soviet-Polish cooperation, which they viewed as the only militarily viable arrangement. Diplomatic manoeuvers continued in the spring and summer of 1939, but in their final attempts, the Franco-British talks with the Soviets in Moscow on forming an anti-Nazi defensive military alliance failed.
== History == Historical and archaeological evidence suggests that mastiffs have long been distinct in both form and function from the similarly large livestock guardian dogs from which they were most likely developed; they also form separate genetic populations. The Fédération Cynologique Internationale and some kennel clubs group the two types together as molossoid dogs; some modern livestock guardian breeds, such as the Pyrenean Mastiff, the Spanish Mastiff and the Tibetan Mastiff, and an extinct draught dog called the Belgian Mastiff, have the word "mastiff" in their name, but are not considered true mastiffs. Many older English sources refer to mastiffs as bandogs or bandogges, although technically the term "bandog" meant a dog that was tethered by a chain (or "bande") that would be released at night; the terms "mastiff" and "bandog" were often used interchangeably. In the twentieth century the term "bandog" was revived to describe some large fighting mastiff type dogs crossed with any bulldog in the United States.
== Origins of biotechnology == Biotechnology arose from the field of zymotechnology or zymurgy, which began as a search for a better understanding of industrial fermentation, particularly beer. Beer was an important industrial, and not just social, commodity. In late 19th-century Germany, brewing contributed as much to the gross national product as steel, and taxes on alcohol proved to be significant sources of revenue to the government. In the 1860s, institutes and remunerative consultancies were dedicated to the technology of brewing. The most famous was the private Carlsberg Institute, founded in 1875, which employed Emil Christian Hansen, who pioneered the pure yeast process for the reliable production of consistent beer. Less well known were private consultancies that advised the brewing industry. One of these, the Zymotechnic Institute, was established in Chicago by the German-born chemist John Ewald Siebel. The heyday and expansion of zymotechnology came in World War I in response to industrial needs to support the war. Max Delbrück grew yeast on an immense scale during the war to meet 60 percent of Germany's animal feed needs. Compounds of another fermentation product, lactic acid, made up for a lack of hydraulic fluid, glycerol. On the Allied side the Russian chemist Chaim Weizmann used starch to eliminate Britain's shortage of acetone, a key raw material for cordite, by fermenting maize to acetone.
Sources: en.wikipedia.org
This ratio is commonly known as the turnover time or flushing time. When applied to liquids, it is also known as the hydraulic retention time (HRT), hydraulic residence time or hydraulic detention time. In the field of chemical engineering this is also known as space time. The residence time of a specific compound in a mixture equals the turnover time (that of the compound, as well as that of the mixture) only if the compound does not take part in any chemical reaction (otherwise its flow is not conservative) and its concentration is uniform. Although the equivalence between the residence time and the ratio
An extension of the WAG algorithm is used, with a new PhyML (WAG+Γ4) model taking into account of sites with different evolutionary rates. Qmaker and nQmaker (2021, 2022), programs with the ability to estimate time-reversible and nonreversible matrices from very large datasets quickly. Each provide a general matrix and 5 specialized matrices, for a total of 12 precalculated substitution matrices. Matrices using a selection of proteins based on structural relatedness, as proposed by Benner et al. (1994), Fan (2004), and Steven et al. (2004). Matrices using structural alignments of proteins instead of simple sequence alignment (6 separate publications). Matrices using known physiochemical parameters of amino acid residues (5 separate publications). For a list of more models (including irreversible i.e. asymmetric and/or specialized ones), see the documentation for recent bioinformatic software including IQ-Tree, PhyML, and RAxML.
Several countries mandate that all travellers, or all foreign travellers, be fingerprinted on arrival and will refuse admission to or even arrest travellers who refuse to comply. In some countries, such as the United States, this may apply even to transit passengers who merely wish to change planes rather than go landside. Fingerprinting countries/regions include Afghanistan, Argentina, Brunei, Cambodia, China, Ethiopia, Ghana, Guinea, India, Japan, Kenya (both fingerprints and a photo are taken), Malaysia upon entry and departure, Mongolia, Saudi Arabia, the Schengen Area, Singapore, South Korea, Taiwan, Thailand, Uganda, the United Arab Emirates and the United States. Many countries also require a photo be taken of people entering the country. The United States, which does not fully implement exit control formalities at its land frontiers (although long mandated by its own legislation), intends to implement facial recognition for passengers departing from international airports to identify people who overstay their visa. Together with fingerprint and face recognition, iris scanning is one of three biometric identification technologies internationally standardised since 2006 by the International Civil Aviation Organization (ICAO) for use in e-passports and the United Arab Emirates conducts iris scanning on visitors who need to apply for a visa. The United States Department of Homeland Security has announced plans to greatly increase the biometric data it collects at US borders.
Prescott DJ, Vagelos PR (1972). "Acyl carrier protein". Advances in Enzymology and Related Areas of Molecular Biology. Advances in Enzymology - and Related Areas of Molecular Biology. Vol. 36. pp. 269–311. doi:10.1002/9780470122815.ch8. ISBN 9780470122815. PMID 4561013. Vance DE, Mitsuhashi O, Bloch K (1973). "Purification and properties of the fatty acid synthetase from Mycobacterium phlei". J. Biol. Chem. 248 (7): 2303–9. doi:10.1016/S0021-9258(19)44110-0. PMID 4698221. Williamson IP, Wakil SJ (1966). "Studies on the mechanism of fatty acid synthesis. XVII. Preparation and general properties of acetyl coenzyme A and malonyl coenzyme A-acyl carrier protein transacylases". J. Biol. Chem. 241 (10): 2326–32. doi:10.1016/S0021-9258(18)96625-1. PMID 5330116. Lowe PN, Rhodes S (1988). "Purification and characterization of acyl-carrier-protein acetyltransferase from Escherichia coli". Biochem. J. 250 (3): 789–96. doi:10.1042/bj2500789. PMC 1148925. PMID 3291856. Tsay JT, Oh W, Larson TJ, Jackowski S, Rock CO (1992). "Isolation and characterization of the β-ketoacyl-acyl carrier protein synthase III gene (fabH) from Escherichia coli K-12". J. Biol. Chem. 267 (10): 6807–14. doi:10.1016/S0021-9258(19)50498-7. PMID 1551888. Rangan VS, Smith S (1997). "Alteration of the substrate specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue". J. Biol. Chem. 272 (18): 11975–8. doi:10.1074/jbc.272.18.11975. PMID 9115261.
== Treatment == The primary treatment of PPID is pergolide, a dopamine agonist that provides suppression to the pars intermedia in place of the dysfunctional hypothalamus. Horses should be reassessed in 30 days following the start of treatment, through evaluation of clinical signs and by baseline diagnostic testing, to ensure the appropriate dose is being prescribed. Results from that test dictate changes in dose. Horses that are responding to treatment should be retested every 6 months, including a test in the autumn when a seasonal increase in ACTH occurs, to ensure their ACTH levels are appropriately suppressed during this time. Drug side effects include a transient decrease in appetite, typically seen when first introducing the medication or increasing the dose, which can be reduced by slowly increasing the dose to therapeutic levels, and by breaking up the daily dose into twice-daily administrations. Attitude, activity levels, hyperglycemia, and increased drinking and urination are usually improved within 30 days of initiating treatment. Other clinical signs, such as hirsutism, potbellied appearance, muscle wasting, laminitic episodes, and increased predisposition to infection, usually take between 30 days and a year to improve. Cyproheptadine may be added to the treatment regimen in horses that are inadequately responding to pergolide, but is usually only used in horses with advanced PPID on high doses of pergolide.
Sources: en.wikipedia.org
== External links == Human HIBADH genome location and HIBADH gene details page in the UCSC Genome Browser. PDBe-KB provides an overview of all the structure information available in the PDB for Human 3-hydroxyisobutyrate dehydrogenase, mitochondrial
Hunkapiller's idea would require competing against his own customers, to all of whom Applied Biosystems sold its sequencing machines and their chemical reagents. However, he calculated that it would also mean doubling the market for that equipment. Hunkapiller brought in Dr. J. Craig Venter to direct the project. Tony White, president of the Perkin-Elmer Corporation backed Hunkapiller on the venture. They organized the new company to accomplish the task. In May 1998, Celera Genomics was formed, to rapidly accelerate the human DNA sequencing process. Dr. Venter boldly declared to the media that he would complete the genome decoding by 2001. That bold announcement prompted the academic consortium to accelerate their own deadline by a couple years, to 2003. Also in 1998, PE Biosystems partnered with Hitachi, Ltd. to develop electrophoresis-based genetic analysis systems, which resulted in their chief new genomics instrument, the ABI PRISM 3700 DNA Analyzer, which advanced the Human Genome sequencing project by nearly five years ahead of schedule. The partnerships sold hundreds of the 3700 analyzers to Celera, and also to others worldwide. The new machine cost US$300,000 each, but was a major leap beyond its predecessor, the 377, and was fully automated, allowing genetic decoding to run around the clock with little supervision. According to Venter, the machine was so revolutionary that it could decode in a single day the same amount of genetic material that most DNA labs could produce in a year.
For infants who have a high-risk of a cows milk allergy but cannot be fed breast milk, there is low-quality evidence suggesting that hydrolyzed protein-based formula may reduce the risk of a cows milk allergy compared to cow milk protein formula.
long arm Denoted in shorthand with the symbol q. In condensed chromosomes where the positioning of the centromere creates two segments or "arms" of unequal length, the longer of the two arms of a chromatid. Contrast short arm.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.